Aisling Capital ^Investors

Aisling Capital is a leading investment firm that focuses on investing in companies developing and commercializing innovative healthcare products, services, and technologies. With over 150 years of combined experience in the healthcare industry, Aisling Capital has a strong track record of investing and returning capital since 2000. The firm currently manages $1.8 billion in assets. A notable achievement of Aisling Capital is the FDA approval of Ohtuvayre (ensifentrine), the first inhaled product with a novel mechanism of action for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients in over 20 years.